Pemetrexed for Treatment of Advanced Non-Small Cell Lung Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 100-105

  Fossella, Frank V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CREATININE; CYANOCOBALAMIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; HOMOCYSTEINE; IRINOTECAN; LOMETREXOL; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; FOLATE METABOLISM; HUMAN; LEG EDEMA; LETHARGY; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RASH; REVIEW; SENSORY NEUROPATHY; SEPSIS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 1242318818     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.001     Document Type: Article

References (23)

1. Calvert H: An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 26:3-10, 1999
2. Mendelsohn LG, Shih C, Chen V, et al: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-47, 1999
3. Teicher BA, Alvarez E, Liu P, et al: MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncot 26:55-62, 1999
4. Worzalla JF, Self TD, Theobald KS, et al: Antitumor therapeutic index of LY309887 is improved with increased folic acid supplementation in mice maintained on a folate deficient diet. Proc Am Assoc Cancer Res 37:383, 1996 (abstr)
5. Niyikiza C, Baker S, Johnson R, et al: Relationship of metabolic profile, drug exposure, and other patient characteristics to toxicity. Ann Oncol 9:620, 1998 (abstr)
6. McDonald AC, Vasey PA, Adams L, et al: A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4:605-610, 1998
7. Rinaldi DA, Burris HA, Dorr FA, et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850, 1995
8. Rinaldi DA, Kuhn JG, Burris HA, et al: A phase I evaluation of the multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380, 1999
9. Hammond L, Baker SD, Villalona-Calero SG, et al: A phase I and pharmacokinetic study of the multitargeted antifolate (MTA) LY231514 with folic acid. Ann Oncol 9:620, 1998 (abstr 620P)
10. Adjei A, Erlichman C, Sloan JA, et al: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757, 2000
11. Thodtmann R, Dumez H, Depenbrock H, et al: Clinical and pharmacokinetic phase I study of MTA (multi-targeted antifolate, LY231514) and paclitaxel in patients with solid tumors administered every 21 days. Proc Am Soc Clin Oncol 18:230a, 1999 (abstr 885)
12. Boyer M, Clarke S, Millward M, et al: Phase I study of pemetrexed and vinorelbine in patients with advanced or metastatic cancer. Ann Oncol 13:24, 2002 (suppl 5) (abstr 85P)
13. Thodtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17:3009-3016, 1999
14. Calvert AH, Hughes AN, Calvert PM, et al: MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. Eur J Cancer 35:S285, 1999 (abstr)
15. Clarke S, Millward M, Findlay M, et al: Activity of the multi-targeted anti-folate MTA in advanced non-small cell lung cancer. Ann Oncol 9:86-87, 1998 (abstr 416P) (suppl 4)
16. Rusthoven J, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced NSCLC: A phase II study. J Clin Oncol 17:1194-1199, 1999
17. Manegold C, Gatzemeier U, von Pawel J, et al: Front-line treatment of advanced non-small cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435-440, 2000
18. Shepherd FA, Dancey J, Arnold A, et al: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer 92:595-600, 2001
19. Zinner RG, Obasaju CK, Fossella FV, et al: Pemetrexed (ALIMTA) plus carboplatin in patients with advanced non-small cell lung cancer: A phase II trial. Proc Am Soc Clin Oncol 22:642, 2003 (abstr 2580)
20. Scagliotti G, Kortsik C, Castellano D, et al: Phase II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 22:625, 2003 (abstr)
21. Ettinger DS, Monnerat C, Kelly K, et al: Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: Importance of survival over response. Proc Am Soc Clin Oncol 21:311a, 2002 (abstr 1243)
22. Smith EF, Mattson K, von Pawel J, et al: ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: A phase 11 study. Ann Oncol 14:455-460, 2003
23. Hanna NH, Shepherd FA, Rosell R, et al: A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 22:622, 2003 (abstr 2503)